CRVS241220P7000
- 1.25
- -0.10-7.41%
Corvus Pharmaceuticals Newsroom
Attackers Targeting VPNs Account for 28.7 Percent of Ransomware Incidents in Q3 According to Corvus Insurance Cyber Threat Report
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
Insider Buyers At Corvus Pharmaceuticals Sitting On US$3.9m Profit
Vaccines stocks in the usa collectively plummet! Trump surprisingly appoints an anti-vaccine advocate as the Secretary of Health in the usa.
① Trump nominated Robert F. Kennedy Jr. as the new Secretary of Health and Human Services, which triggered a sell-off in vaccine companies; ② Kennedy advocates very radical views, opposing vaccines since 2005, and questioning the transparency of the usa government in public health information.
Corvus Pharmaceuticals Presents New Preclinical Data Supporting Soquelitinib's Efficacy in Systemic Sclerosis at ACR Convergence 2024
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
A Quick Look at Today's Ratings for Corvus Pharmaceuticals(CRVS.US), With a Forecast Between $13 to $24
An Intrinsic Calculation For Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Suggests It's 41% Undervalued
Corvus Pharma Analyst Ratings
Corvus Pharmaceuticals Price Target Raised to $14 From $8 at Oppenheimer
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript Summary
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript
Corvus Pharmaceuticals Reports Q3 EPS (60c), Consensus (11c)
Express News | Corvus Pharma Q3 2024 GAAP EPS $(0.60) Misses $(0.11) Estimate
Corvus Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Corvus Pharmaceuticals | 8-K: Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
Corvus Pharmaceuticals 3Q Loss/Shr 60c >CRVS
Here Are the Major Earnings After the Close Today
An Overview of Corvus Pharma's Earnings